Breast Cancer

Taking Zoledronic Acid Less Often After the First Year of Treatment Is Safe for Women with Metastatic Breast Cancer

ASCO Annual Meeting
May 30, 2014

According to new findings from a phase III clinical trial, women taking zoledronic acid (Zometa) for breast cancer that has spread to the bone, called metastases, can safely scale back to a once-every-three-months schedule after finishing a year of monthly treatments.

Most Women Have an Inaccurate Perception of Their Breast Cancer Risk

Breast Cancer Symposium
September 4, 2013

A large-scale survey of Long Island women who were having mammography to screen for breast cancer shows that the majority (more than 90%) either under- or overestimated their risk of developing this disease during their lifetime. Additionally, four out of every 10 women surveyed (40%) said they had never discussed their personal breast cancer risk with a doctor.


Subscribe to RSS - Breast Cancer